EMERGENT BIOSOLUTIONS INC. Effective Income Tax Rate Reconciliation, Tax Contingency, Amount
EMERGENT BIOSOLUTIONS INC. (EBS) reported Effective Income Tax Rate Reconciliation, Tax Contingency, Amount of -$3.50 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxContingencies · last filed 2026-02-27
- EMERGENT BIOSOLUTIONS INC. effective income tax rate reconciliation, tax contingency, amount for fiscal 2024 was -$3.50M.
- EMERGENT BIOSOLUTIONS INC. effective income tax rate reconciliation, tax contingency, amount for fiscal 2023 was -$600.00K.
- EMERGENT BIOSOLUTIONS INC. effective income tax rate reconciliation, tax contingency, amount for fiscal 2022 was -$9.00M, a 850.00% decline from fiscal 2021.
- EMERGENT BIOSOLUTIONS INC. effective income tax rate reconciliation, tax contingency, amount for fiscal 2021 was $1.20M, a 45.45% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount 12 month as first filed |
|---|---|---|
| 2024-12-31 | -$3.50M 10-K · filed 2026-02-27 | |
| 2023-12-31 | -$600.00K 10-K · filed 2026-02-27 | |
| 2022-12-31 | -$9.00M 10-K · filed 2025-03-04 | -$9.70M 10-K · filed 2023-03-01 |
| 2021-12-31 | $1.20M 10-K · filed 2024-03-08 | $300.00K 10-K · filed 2022-02-25 |
| 2020-12-31 | $2.20M 10-K/A · filed 2023-12-11 | -$300.00K 10-K · filed 2021-02-19 |
| 2019-12-31 | $1.10M 10-K · filed 2022-02-25 | |
| 2018-12-31 | $300.00K 10-K · filed 2021-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |